• Nymox Pharmaceutical (Hasbrouck Heights, New Jersey) said that positive results from clinical studies of the company's AlzheimAlert test will be presented at the annual meeting of the American Psychiatric Association in Toronto later this month. The AlzheimAlert test is a urine-based diagnostic aid for Alzheimer's disease (AD). It is the only proven accurate non-invasive AD test technology available. The test has the CE mark in Europe, and is CLIA certified as a laboratory test service which is available in the U.S.

• Provectus Pharmaceuticals (Knoxville, Tennessee), a developer of pharmaceutical technologies for the treatment of breast cancer, liver cancer and metastatic melanoma, reported that it has received U.S. patent No. 7,036,516. The patent covers use of advanced laser technologies in the selective destruction of pigmented tissue, such as moles and pigmented skin cancers, including melanomas. Additional areas of applicability include selective destruction of hair follicles for hair reduction along with tattoo removal.

• Staar Surgical (Monrovia, California) reported that it has submitted a premarket approval (PMA) supplement to the FDA for the Visian TICL, a toric implantable Collamer lens designed to treat both nearsightedness and astigmatism. Staar submitted the Visian TICL application as a supplement to the PMA for its Myopic Visian ICL, which the FDA approved in December 2005 for use in correction of myopia in adults and which is now available to patients in the U.S. The Visian TICL supplemental filing supports an indication for use in adults 21 to 45 years of age for the correction of myopia ranging from -3.0 to -20 diopters with astigmatism of 1 to 4 diopters.